Original Articles
Vol. 16 (2021)
https://doi.org/10.3269/1970-5492.2021.16.32

EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
139
Views
95
Downloads

Authors

Antonio Gennaro Nicotera
antonionicotera@gmail.com
Unit of Child Neurology and Psychiatry, Department of Human Pathology of the Adult and Developmental Age, "Gaetano Barresi" University of Messina, Messina, Italy, Italy.
Laura Turriziani
Unit of Child Neurology and Psychiatry, Department of Human Pathology of the Adult and Developmental Age, "Gaetano Barresi" University of Messina, Messina, Italy, Italy.
Giulia Spoto
Unit of Child Neurology and Psychiatry, Department of Human Pathology of the Adult and Developmental Age, "Gaetano Barresi" University of Messina, Messina, Italy, Italy.
Greta Amore
Unit of Child Neurology and Psychiatry, Department of Human Pathology of the Adult and Developmental Age, "Gaetano Barresi" University of Messina, Messina, Italy, Italy.
Maria Midiri
Unit of Child Neurology and Psychiatry, Department of Human Pathology of the Adult and Developmental Age, "Gaetano Barresi" University of Messina, Messina, Italy, Italy.
Gabriella Di Rosa
Unit of Child Neurology and Psychiatry, Department of Human Pathology of the Adult and Developmental Age, "Gaetano Barresi" University of Messina, Messina, Italy, Italy.
Among the newest antiepileptic drugs, brivaracetam (BRV), previously known as “ucb34714”, is
one of the most interesting molecules available, increasingly getting the attention of researchers.
The clinical efficacy of BRV as adjunctive therapy has been extensively assessed in six
randomized, controlled, phase III trials, the results of which demonstrated BRV efficacy in
reducing seizures at the dosage of 20–200 mg/day. However, to date, only few data on the pediatric
population are available. Here we briefly report the data available on BRV and its usage in the
pediatric population suffering from epilepsy to highlight the potential benefits of this drug in this
population.

Downloads

Download data is not yet available.

How to Cite



EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE. (2025). EuroMediterranean Biomedical Journal, 16. https://doi.org/10.3269/1970-5492.2021.16.32
Copyright (c) 2025 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.